drugset / Trial / NCT00107861

Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases

NCT00107861 ↗

Phase 1/2 Completed 44 enrolled Biogen
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will be conducted in subjects with refractory colorectal carcinoma with unresectable liver metastases. The purposes of the study are: * to evaluate the safety and any harmful effects of an intravenous injection of Ad.hIFN-β; * help determine whether the virus carrying the interferon-beta gene will enter the bloodstream and liver tumor cells and cause the cancer cells to die.

Timeline

Start
2005-05
Primary completion
—
Completion
2006-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Ad.hIFN-β Unknown — Intravenous